FUDR-Dex (** Generic (floxuridine + dexamethasone combination) **)

Other Medications

EU Not submitted to EMA ES Not available 1 Clinical Trials

Description

FUDR-Dex is used in the treatment of colorectal cancer (CRC) as an investigational therapy; its efficacy and safety are currently being evaluated in clinical trials. It may be administered via intra-arterial infusion to target tumor cells directly, potentially reducing systemic toxicity compared to traditional chemotherapy.

Mechanism of Action

FUDR-Dex combines floxuridine, a fluoropyrimidine antimetabolite that interferes with DNA synthesis by inhibiting thymidylate synthase and dexamethasone, an anti-inflammatory corticosteroid which may enhance the efficacy of floxuridine through its anti-inflammatory effects.

Side Effects

Neutropenia; diarrea; náuseas y vómitos; reacciones alérgicas; elevación de los niveles de azúcar en sangre;

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT03366155 Phase 2
Completed
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
United States

Quick Info

Brand Name** Generic (floxuridine + dexamethasone combination) **
CategoryOther Medications
EU EMA StatusNot submitted to EMA
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
786 trials
Leucovorin
Other Medications
647 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.